Triple-class refractory multiple myeloma a ‘launching pad’ for groundbreaking therapies
The last few years have seen major therapeutic advancements in the field of triple-class refractory multiple myeloma.
Elotuzumab-based quadruplet produces durable responses in newly diagnosed multiple myeloma
A quadruplet regimen comprising the monoclonal antibody elotuzumab plus weekly carfilzomib, lenalidomide and dexamethasone conferred a 72% 3-year PFS rate among patients with newly diagnosed multiple myeloma, phase 2 trial results showed.
Dual-target CAR-T ‘very promising’ for advanced multiple myeloma
CHICAGO — A single dose of an investigational chimeric antigen receptor T-cell therapy induced an objective response in nearly 90% of patients with relapsed or refractory multiple myeloma, phase 1 study results showed.
VIDEO: DETERMINATION study potentially significant for myeloma treatment
In this video, Paul Richardson, MD, director of clinical research at Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, discusses the phase III DETERMINATION study in multiple myeloma presented at ASCO Annual Meeting.
Study finds ‘substantial’ underrepresentation of Black patients in CAR-T clinical trials
Black patients appeared consistently underrepresented in pivotal clinical trials that led to FDA approval of several chimeric antigen receptor T-cell therapies, according to findings published in JAMA Network Open.
CAR-T shows ‘promising’ effectiveness for high-risk multiple myeloma
SALT LAKE CITY — Ciltacabtagene autoleucel induced a 95% overall response rate among patients with multiple myeloma who had early relapse after front-line therapy, according to results of a cohort analysis from the CARTITUDE-2 trial.
Predicting early relapse in multiple myeloma an ‘area of unmet need’
As oncologists currently lack a cure for multiple myeloma, most patients will relapse at some point. The ability to predict when this will occur, however, may lead to more personalized therapy.
FDA approves Carvykti as second CAR T-cell therapy for advanced multiple myeloma
The FDA approved ciltacabtagene autoleucel, a chimeric antigen receptor T-cell therapy for treatment of adults with relapsed or refractory multiple myeloma.
Managing multiple myeloma during COVID-19 pandemic
In the last year, the COVID-19 pandemic created panic and uncertainty for everyone, but most notably individuals with cancer and other immunosuppressing diseases, and their providers.
CAR T-cell therapy, bispecific T-cell engagers, other exciting treatments in multiple myeloma
Maung Myo Htut, MD, associate clinical professor in the division of multiple myeloma within the department of hematology and hematopietic cell transplantation at City of Hope, discussed treatment developments in multiple myeloma, including exciting data from ASH 2020, the role of CAR T-cell therapy, autologous hematopoietic stem cell transplant, consolidation therapy and more.